The Familial Adenomatous Polyposis drugs in development market research report provides comprehensive information on the therapeutics under development for Familial Adenomatous Polyposis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Familial Adenomatous Polyposis. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Familial Adenomatous Polyposis and features dormant and discontinued products.
GlobalData tracks 19 drugs in development for Familial Adenomatous Polyposis by 18 companies/universities/institutes. The top development phase for Familial Adenomatous Polyposis is preclinical with seven drugs in that stage. The Familial Adenomatous Polyposis pipeline has 17 drugs in development by companies and two by universities/ institutes. Some of the companies in the Familial Adenomatous Polyposis pipeline products market are: Recursion Pharmaceuticals, TheraCryf and Biodexa Pharmaceuticals.
The key targets in the Familial Adenomatous Polyposis pipeline products market include Ornithine Decarboxylase, Platelet Derived Growth Factor Receptor, and Serine/Threonine Protein Kinase mTOR.
The key mechanisms of action in the Familial Adenomatous Polyposis pipeline product include Ornithine Decarboxylase Inhibitor with two drugs in Filing rejected/Withdrawn. The Familial Adenomatous Polyposis pipeline products include one routes of administration with the top ROA being Oral and six key molecule types in the Familial Adenomatous Polyposis pipeline products market including Small Molecule, and Synthetic Peptide.
Familial Adenomatous Polyposis overview
Familial adenomatous polyposis (FAP) or classic FAP is a genetic condition that causes extra tissue (polyps) to form in large intestine and rectum. It is caused by germline mutations in the APC gene. Symptoms include blood or mucus in the stools, diarrhea or constipation, weight loss due to unknown reason, and abdominal pain. Treatment includes surgery and medications such as non-steroidal anti-inflammatory drugs (NSAIDs).
For a complete picture of Familial Adenomatous Polyposis’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
